RxDoctor Payments Data

Rahul Abhyankar, MD

Neurology · Carmel, INNPI 1659768505

Payments from drug & device makers

$23,406in general payments, 2019–2025

Across 1,530 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • UCB, Inc.$2K
  • MDD US Operations, LLC$1K
  • Pfizer$1000
  • Lilly USA, LLC$919
  • AstraZeneca$868
  • plus $14K from 54 others

What the payments were for

  • Speaking & faculty fees$340%
  • Food & beverage$23,26999%
  • Education$1040%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)293$3,712
UCB, Inc.118$1,735
MDD US Operations, LLC63$1,029
Pfizer83$1,000
Lilly USA, LLC84$919
AstraZeneca(2 entities)39$868
Argenx US, Inc.48$784
Amgen(2 entities)43$774
Teva Pharmaceuticals USA, Inc.50$713
Novartis52$688
Neurocrine Biosciences, Inc.46$627
EMD Serono, Inc.30$588
SK Life Science, Inc.30$531
Neurelis, Inc.35$514
Alnylam Pharmaceuticals Inc.22$480
Jazz Pharmaceuticals Inc.23$473
Eisai Inc.32$446
Acadia Pharmaceuticals Inc29$403
Livanova USA, Inc.21$399
Lundbeck LLC19$364
CSL Behring17$342
Amneal Pharmaceuticals LLC19$323
Catalyst Pharmaceuticals, Inc.13$308
Impel Pharmaceuticals Inc.22$304
Axsome Therapeutics, Inc.19$285
Takeda Pharmaceuticals U.S.A., Inc.13$267
Sumitomo Pharma America, Inc.14$265
Supernus Pharmaceuticals, Inc.19$260
Biohaven Pharmaceutical Holding Company Ltd.19$251
Vanda Pharmaceuticals Inc.10$246
Avanir Pharmaceuticals, Inc.12$222
Octapharma USA, Inc.11$213
TG Therapeutics, Inc.10$205
Genentech USA, Inc.10$191
Otsuka America Pharmaceutical, Inc.13$191
Johnson & Johnson12$183
Sanofi8$164
Tanabe Pharma America, Inc.11$162
Xeris Pharmaceuticals, Inc.9$160
Harmony Biosciences LLC13$157
Biohaven Pharmaceuticals, Inc.12$153
Sunovion Pharmaceuticals Inc.7$148
Arbor Pharmaceuticals, Inc.7$138
Greenwich Biosciences, Inc.6$98
Aprecia Pharmaceuticals, LLC6$89
Currax Pharmaceuticals LLC6$86
Springworks Therapeutics, Inc.4$79
Acorda Therapeutics, Inc4$75
Bristol Myers Squibb5$71
Adamas Pharmaceuticals, Inc.3$62
Grifols USA, LLC3$57
Collegium Pharmaceutical, Inc.3$55
OWP Pharmaceuticals, Inc.3$53
Upsher-smith Laboratories LLC3$52
Scilex Pharmaceuticals Inc.3$48
Biogen3$47
Almatica Pharma LLC2$44
ANI Pharmaceuticals, Inc.2$42
Cala Health, Inc.2$40
Abbott2$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,406 in reported general payments places this provider in the 75th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$1,216,053
Medicare patients
555
Services billed
29,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate16$134,625
Nurtec OdtRimegepant Sulfate18$19,879
UbrelvyUbrogepant19$19,092
Lacosamide21$6,517
Gabapentin89$1,929
Propranolol Hcl ErPropranolol Hcl43$1,922
Carbidopa-LevodopaCarbidopa/Levodopa68$1,895
Levetiracetam55$1,681
Pregabalin37$1,579
Mycophenolate Mofetil17$1,479
Pyridostigmine Bromide14$913
Carbamazepine14$859
Duloxetine Hcl37$782
Pramipexole DihydrochloridePramipexole Di-Hcl15$684
Memantine Hcl31$644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$627$134,62516 claims
PfizerNurtec Odt$1,000$19,87918 claims
AbbVieUbrelvy$3,712$19,09219 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$323$2,39231 claims
Upsher-smith Laboratories LLCTopiramate$52$36311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 308 neurology providers in Indiana.

Other neurology in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →